Literature DB >> 11818484

Cancer gene therapy: scientific basis.

Punit D Wadhwa1, Steven P Zielske, Justin C Roth, Christopher B Ballas, Janice E Bowman, Stanton L Gerson.   

Abstract

Gene therapy of cancer has been one of the most exciting and elusive areas of therapeutic research in the past decade. Critical developments have occurred in gene therapy targeting cancer cells, cancer vasculature, the immune system, and the bone marrow, itself often the target for severe toxicity from therapeutic agents. We review some recent developments in the field. In each instance, clear preclinical models validated the therapeutic approach and efforts have been made to evaluate the target impact in both preclinical and early clinical trials. Although no cures can consistently be expected from today's cancer gene therapy, the rapid progress may imply that such cures are a few short years away.

Entities:  

Mesh:

Year:  2002        PMID: 11818484     DOI: 10.1146/annurev.med.53.082901.104039

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  16 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  DNA repair proteins as molecular targets for cancer therapeutics.

Authors:  Mark R Kelley; Melissa L Fishel
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

Review 3.  Gene therapy for gastric cancer: a review.

Authors:  Chao Zhang; Zhan-Kui Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

4.  Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells.

Authors:  Padmaja Magadala; Mansoor Amiji
Journal:  AAPS J       Date:  2008-11-26       Impact factor: 4.009

5.  AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models.

Authors:  Chie-Schin Shih; Nikia Laurie; Jeremy Holzmacher; Yunyu Spence; Amit C Nathwani; Andrew M Davidoff; Michael A Dyer
Journal:  Neuromolecular Med       Date:  2009-03-22       Impact factor: 3.843

Review 6.  Molecular medicine: promises, promises?

Authors:  Michael Steel
Journal:  J R Soc Med       Date:  2005-05       Impact factor: 18.000

7.  Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response.

Authors:  Pei-Ming Chu; Shih-Hwa Chiou; Tsann-Long Su; Yi-Jang Lee; Li-Hsin Chen; Yi-Wei Chen; Sang-Hue Yen; Ming-Teh Chen; Ming-Hsiung Chen; Yang-Hsin Shih; Pang-Hsien Tu; Hsin-I Ma
Journal:  Radiat Oncol       Date:  2011-01-19       Impact factor: 3.481

8.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

9.  Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Authors:  Jing-Hua Huang; Song-Nan Zhang; Kyung-Ju Choi; Il-Kyu Choi; Joo-Hang Kim; Min-Geol Lee; Mingul Lee; Hoguen Kim; Chae-Ok Yun
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

10.  Nanomaterials in the application of tumor vaccines: advantages and disadvantages.

Authors:  Xd Li; Jy Gao; Y Yang; Hy Fang; Yj Han; Xm Wang; W Ge
Journal:  Onco Targets Ther       Date:  2013-06-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.